Aliases & Classifications for Hemarthrosis

MalaCards integrated aliases for Hemarthrosis:

Name: Hemarthrosis 12 56 45 15 17 74
Hemarthrosis Involving Pelvic Region and Thigh 12
Haemarthrosis of the Pelvic Region and Thigh 12
Hemarthrosis of the Pelvic Region and Thigh 12
Hemarthrosis Involving Shoulder Region 12
Hemarthrosis Involving Ankle and Foot 12
Hemarthrosis of the Ankle and/or Foot 12
Haemarthrosis of the Ankle and Foot 12
Hemarthrosis of the Shoulder Region 12
Hemarthrosis of the Ankle and Foot 12
Hemarthrosis of Ankle and/or Foot 12
Hemarthrosis Involving Lower Leg 12
Hemarthrosis Involving Upper Arm 12
Haemarthrosis of Shoulder Joint 12
Hemarthrosis of Shoulder Region 12
Hemarthrosis Involving Forearm 12
Hemarthrosis of the Lower Leg 12
Hemarthrosis of the Upper Arm 12
Hemarthrosis Involving Hand 12
Hemarthrosis of the Forearm 12
Hemarthrosis of Lower Leg 12
Hemarthrosis of Upper Arm 12
Hemarthrosis of Shoulder 12
Hemarthrosis of the Hand 12
Hemarthrosis of Forearm 12
Hemarthrosis of Hand 12

Classifications:



External Ids:

Disease Ontology 12 DOID:801
ICD9CM 36 719.1 719.10
MeSH 45 D006395
SNOMED-CT 69 81808003
ICD10 34 M25.0
UMLS 74 C0018924

Summaries for Hemarthrosis

MalaCards based summary : Hemarthrosis, also known as hemarthrosis involving pelvic region and thigh, is related to factor x deficiency and factor vii deficiency, and has symptoms including arthralgia, hemoptysis and metatarsalgia. An important gene associated with Hemarthrosis is F8 (Coagulation Factor VIII), and among its related pathways/superpathways are Metabolism of proteins and Response to elevated platelet cytosolic Ca2+. The drugs Anti-inhibitor coagulant complex and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include bone, skeletal muscle and b cells, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 77 Hemarthrosis is a bleeding into joint spaces. It is a common feature of... more...

Related Diseases for Hemarthrosis

Diseases related to Hemarthrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 factor x deficiency 31.6 F10 F7 F9 VWF
2 factor vii deficiency 31.3 F10 F7 F8 F9
3 factor v deficiency 30.4 F10 F7 F8 F9 VWF
4 acquired hemophilia 30.1 F10 F8 F9
5 acquired hemophilia a 30.0 F8 F9
6 hemophilia 29.9 F7 F8 F9 VWF
7 arthropathy 29.9 F8 F9
8 factor viii deficiency 29.7 F8 VWF
9 glanzmann thrombasthenia 29.5 F8 F9 VWF
10 von willebrand's disease 29.3 F8 F9 VWF
11 hemophilia b 29.3 F10 F7 F8 F9
12 myocardial infarction 29.3 F10 F7 F8 VWF
13 hemophilia a 29.1 F10 F7 F8 F9 VWF
14 hemorrhagic disease 28.6 F10 F7 F8 F9 VWF
15 afibrinogenemia, congenital 11.1
16 factor xiii deficiency 11.1
17 synovitis 10.3
18 arthritis 10.2
19 cardiac tamponade 10.1 F8 F9
20 factor xi deficiency 10.1
21 acute myocardial infarction 10.1
22 pigmented villonodular synovitis 10.1
23 villonodular synovitis 10.1
24 thrombasthenia 10.1
25 malignant skin fibrous histiocytoma 10.1 F7 F9
26 malignant dermis tumor 10.1 F7 F9
27 papillary cystadenocarcinoma 10.0 BGLAP SPP1
28 disseminated intravascular coagulation 10.0 F7 F9
29 osteoarthritis 10.0
30 purpura 10.0
31 fibrosarcomatous osteosarcoma 10.0 BGLAP SPP1
32 carotid stenosis 10.0 F7 SPP1
33 hypophosphatasia, adult 10.0 BGLAP SPP1
34 fainting 10.0 F8 VWF
35 cerebral arteritis 10.0 F8 VWF
36 osteofibrous dysplasia 9.9 BGLAP SPP1
37 brachydactyly, type d 9.9 F8 VWF
38 von willebrand disease, type 1 9.9 F8 VWF
39 bone resorption disease 9.9 BGLAP SPP1
40 intracranial thrombosis 9.9 F8 VWF
41 von willebrand disease, type 3 9.9 F8 VWF
42 lymphangiosarcoma 9.9 F8 VWF
43 antiphospholipid syndrome 9.8 F10 VWF
44 systemic lupus erythematosus 9.8
45 rheumatoid arthritis 9.8
46 thrombocytopenic purpura, autoimmune 9.8
47 reflex sympathetic dystrophy 9.8
48 psoriatic arthritis 9.8
49 arteriovenous fistula 9.8
50 hemangioma 9.8

Graphical network of the top 20 diseases related to Hemarthrosis:



Diseases related to Hemarthrosis

Symptoms & Phenotypes for Hemarthrosis

UMLS symptoms related to Hemarthrosis:


arthralgia, hemoptysis, metatarsalgia, other symptoms referable to joint, stiffness of joint, not elsewhere classified in icd10cm

MGI Mouse Phenotypes related to Hemarthrosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.55 F10 F7 F9 SPP1 VWF
2 homeostasis/metabolism MP:0005376 9.43 F10 F7 F8 F9 SPP1 VWF
3 mortality/aging MP:0010768 9.1 F10 F7 F8 F9 SPP1 VWF

Drugs & Therapeutics for Hemarthrosis

Drugs for Hemarthrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anti-inhibitor coagulant complex Approved, Investigational Phase 4,Phase 3,Not Applicable
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
4
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
5
Benzocaine Approved, Investigational Phase 4,Phase 3 94-09-7, 1994-09-7 2337
6
tannic acid Approved Phase 4,Phase 3 1401-55-4
7
Tranexamic Acid Approved Phase 4,Not Applicable 1197-18-8 5526
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
rituximab Approved Phase 4 174722-31-7 10201696
11 Factor VIII Phase 4,Phase 3,Phase 2,Not Applicable
12 Coagulants Phase 4,Phase 3,Phase 2,Not Applicable
13 Hemostatics Phase 4,Phase 2,Not Applicable
14 Triamcinolone hexacetonide Phase 4
15 Viscosupplements Phase 4,Not Applicable
16 Hylan Phase 4
17 Adjuvants, Immunologic Phase 4,Not Applicable
18 Protective Agents Phase 4,Not Applicable
19 triamcinolone acetonide Phase 4
20 Immunologic Factors Phase 4,Phase 3,Not Applicable
21 Triamcinolone diacetate Phase 4
22 Antifibrinolytic Agents Phase 4,Not Applicable
23 Acetaminophen, hydrocodone drug combination Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Antineoplastic Agents, Immunological Phase 4,Phase 1
26 Hormones Phase 4
27 Antirheumatic Agents Phase 4
28 glucocorticoids Phase 4
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
30 Antineoplastic Agents, Hormonal Phase 4
31 Hormone Antagonists Phase 4
32
Thrombin Approved, Investigational Phase 3,Not Applicable
33 Immunoglobulins Phase 3
34 Antibodies Phase 3
35 Immunoglobulin Fc Fragments Phase 3
36 BAX 855 Phase 3
37 Pharmaceutical Solutions Phase 3
38 Antibodies, Bispecific Phase 3
39
Rivaroxaban Approved Phase 2 366789-02-8
40
Apixaban Approved Phase 2 503612-47-3 10182969
41
Enoxaparin Approved Phase 2 9005-49-6 772
42
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
43 HIV Protease Inhibitors Phase 2
44
protease inhibitors Phase 2
45 Antithrombins Phase 2
46 Factor Xa Inhibitors Phase 2
47 Serine Proteinase Inhibitors Phase 2
48 Antithrombin III Phase 2
49 Anticoagulants Phase 2,Not Applicable
50
Bevacizumab Approved, Investigational Phase 1 216974-75-3

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
2 A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children Unknown status NCT02999308 Phase 4
3 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
4 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
5 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
6 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Completed NCT00586521 Phase 4 Kogenate (BAY14-2222)
7 Viscosupplementation in Patients With Hemophilic Arthropathy Completed NCT01748201 Phase 4
8 Russian Kogenate Pediatric Study Completed NCT00632814 Phase 4 rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
9 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A Completed NCT01810666 Phase 4
10 Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy Completed NCT00638001 Phase 4
11 Canadian Hemophilia Prophylaxis Study Completed NCT01085344 Phase 4
12 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens Completed NCT00927667 Phase 4
13 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A Completed NCT02697370 Phase 4 Pharmacokinetic based dosage change
14 China ADVATE PTP Study Completed NCT02170402 Phase 4
15 Reducing Hemarthrosis in High Tibial Osteotomy and Tibial Tubercle Osteotomy Recruiting NCT03606109 Phase 4 Intravenous Tranexamic Acid (TXA)
16 Reducing Hemarthrosis in Anterior Cruciate Ligament Reconstruction With BTB Autograft by the Administration of Intravenous Tranexamic Acid: A Double-Blind Randomized Control Study Recruiting NCT03631355 Phase 4 Tranexamic Acid
17 Pharmacokinetic (PK)Research on Chinese Children of Hemophilia Recruiting NCT03622476 Phase 4 concentrated FVIII
18 Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China Recruiting NCT03598725 Phase 4 Coagulation Factor VIII;Prednisone;Rituximab
19 Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B Completed NCT00364182 Phase 3 Recombinant Coagulation Factor IX (BeneFIX);Recombinant Coagulation Factor IX (BeneFIX)
20 Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A Completed NCT01454739 Phase 3 rFVIIIFc
21 Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B Completed NCT01425723 Phase 3
22 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A Completed NCT01458106 Phase 3 BIIB031 (rFVIIIFc);FVIII (PK subgroup only)
23 Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B Completed NCT01440946 Phase 3 rFIXFc;FIX
24 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A Completed NCT01181128 Phase 3 Factor VIII (rFVIIIFc);Advate®
25 BAX 855 PK-guided Dosing Completed NCT02585960 Phase 3
26 Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor Completed NCT00851721 Phase 3
27 Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII Completed NCT00543439 Phase 3
28 Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX Recruiting NCT03754790 Phase 3 Fitusiran
29 A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis Recruiting NCT03549871 Phase 3 Fitusiran
30 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors Recruiting NCT03417245 Phase 3 fitusiran;factor VIII or factor IX
31 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors Recruiting NCT03417102 Phase 3 fitusiran;recombinant Factor VIIa and FEIBA
32 Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B Active, not recruiting NCT02234310 Phase 3
33 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A Active, not recruiting NCT03020160 Phase 3 Emicizumab
34 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors Active, not recruiting NCT02795767 Phase 3 Emicizumab
35 A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Active, not recruiting NCT02847637 Phase 3 Emicizumab
36 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors Active, not recruiting NCT02622321 Phase 3 Emicizumab;rFVIIa;aPCC
37 Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants Active, not recruiting NCT03315455 Phase 3 Emicizumab
38 A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A Active, not recruiting NCT01580293 Phase 2, Phase 3
39 An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A Active, not recruiting NCT02234323 Phase 3
40 Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A Not yet recruiting NCT03815318 Phase 3 Recombinant Human Coagulation FVIII
41 A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B Not yet recruiting NCT03861273 Phase 3
42 rVWF Pediatric and Adult Study Not yet recruiting NCT03879135 Phase 3
43 Early Prophylaxis Immunologic Challenge (EPIC) Study Terminated NCT01376700 Phase 3
44 rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors Unknown status NCT01105546 Phase 2 recombinant activated factor VII;recombinant activated factor VII
45 Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy Unknown status NCT01629381 Phase 2 Rivaroxaban;placebo
46 Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds Completed NCT00486278 Phase 2 eptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated)
47 Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII Completed NCT00245245 Phase 2 recombinant porcine coagulation factor VIII (OBI-1)
48 A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery Completed NCT03251482 Phase 2 JNJ-64179375 0.3 mg/kg;JNJ-64179375 0.6 mg/kg;JNJ-64179375 1.2 mg/kg;JNJ-64179375 (Dose to be Determined);JNJ-64179375 A mg/kg;JNJ-64179375 B mg/kg;JNJ-64179375 C mg/kg;JNJ-64179375 D mg/kg;Placebo JNJ-64179375;Apixaban placebo;Apixaban 2.5 mg
49 A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy Recruiting NCT02994147 Phase 2 Placebo;AC-201CR
50 A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery Not yet recruiting NCT03891524 Phase 2 JNJ-70033093 25 mg;JNJ-70033093 50 mg;JNJ-70033093 100 mg;JNJ-70033093 200 mg;JNJ-70033093, dose to be determined;Placebo;Enoxaparin 40 mg

Search NIH Clinical Center for Hemarthrosis

Cochrane evidence based reviews: hemarthrosis

Genetic Tests for Hemarthrosis

Anatomical Context for Hemarthrosis

MalaCards organs/tissues related to Hemarthrosis:

42
Bone, Skeletal Muscle, B Cells, Myeloid, Monocytes

Publications for Hemarthrosis

Articles related to Hemarthrosis:

(show top 50) (show all 246)
# Title Authors Year
1
Single Intravenous Administration of Tranexamic Acid in Anterior Cruciate Ligament Reconstruction to Reduce Postoperative Hemarthrosis and Increase Functional Outcomes in the Early Phase of Postoperative Rehabilitation: A Randomized Controlled Trial. ( 30611343 )
2019
2
Recurrent Hemarthrosis After Total Knee Arthroplasty: Evaluation and Treatment. ( 30720569 )
2019
3
Treatment of Recurrent Hemarthrosis after Total Knee Arthroplasty. ( 29715715 )
2018
4
Severe Ankle Arthritis After Multiple Hemarthrosis Secondary to Factor XI Deficiency: A Case Report. ( 29891129 )
2018
5
Homeopathic Medicine Reduces Pain and Hemarthrosis in Moderate and Severe Hemophilia: A Multicentric Study. ( 29807367 )
2018
6
Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis: A case report and literature review. ( 30235659 )
2018
7
Tranexamic Acid Reduces Perioperative Blood Loss and Hemarthrosis in Total Ankle Arthroplasty. ( 30180225 )
2018
8
An unusual case of pigmented villonodular synovitis after total knee arthroplasty presenting with recurrent hemarthrosis. ( 30560170 )
2018
9
Endovascular Management of Recurrent Spontaneous Hemarthrosis After Arthroplasty. ( 27882429 )
2017
10
Embolization of the Geniculate Arteries Is an Effective Treatment of Recurrent Hemarthrosis Following Total Knee Arthroplasty That Can Be Safely Repeated. ( 29224993 )
2017
11
Hemarthrosis and scurvy. ( 28433625 )
2017
12
Hemarthrosis subtalar, a rare diagnosis. ( 28409144 )
2017
13
Recurrent Hemarthrosis due to Iatrogenic AVF Treated With Onyx Embolization. ( 28446073 )
2017
14
Spontaneous elbow hemarthrosis identified by point-of-care ultrasound. ( 28435904 )
2017
15
Capsulotomy as a measure to control pain and reducing hemarthrosis in arthroscopic DB ACL reconstruction surgery: a prospective randomized control study. ( 29086025 )
2017
16
Acute hemophilic hemarthrosis: is local cryotherapy recommended? ( 29020808 )
2017
17
Reducing Intra-articular Hemarthrosis After Arthroscopic ACL Reconstruction: Response. ( 26929179 )
2016
18
Reducing Intra-articular Hemarthrosis After Arthroscopic ACL Reconstruction: Letter to the Editor. ( 26929178 )
2016
19
Acute Hemarthrosis of the Knee Caused by Arteriovenous Malformation. ( 27231206 )
2016
20
Technically Successful Geniculate Artery Embolization Does Not Equate Clinical Success for Treatment of Recurrent Knee Hemarthrosis after Knee Surgery. ( 26806692 )
2016
21
Geniculate Artery Embolization for Management of Recurrent Hemarthrosis: A Single-Center Experience. ( 27338503 )
2016
22
Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. ( 28039188 )
2016
23
Spontaneous Recurrent Hemarthrosis of the Knee: A Report of Two Cases with a Source of Bleeding Detected during Arthroscopic Surgery of the Knee Joint. ( 27703824 )
2016
24
Spontaneous Hemarthrosis of the Knee - Late Complication of Flexible Femur Nailing: A Case Report. ( 28180118 )
2016
25
Epidemiology of intra- and peri-articular structural injuries in traumatic knee joint hemarthrosis - data from 1145 consecutive knees with subacute MRI. ( 27374877 )
2016
26
Effects of hemarthrosis on cartilage and synovium in rabbits. ( 26936196 )
2016
27
Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data. ( 25729030 )
2015
28
LASER versus electromagnetic field in treatment of hemarthrosis in children with hemophilia. ( 26306883 )
2015
29
Geniculate artery embolization for recurrent postarthroplasty hemarthrosis of the knee. ( 27398122 )
2015
30
Reducing Intra-articular Hemarthrosis After Arthroscopic Anterior Cruciate Ligament Reconstruction by the Administration of Intravenous Tranexamic Acid: A Prospective, Randomized Controlled Trial. ( 26337246 )
2015
31
Recurrent Hemarthrosis Following Knee Arthroplasty Treated with Arterial Embolization. ( 26092252 )
2015
32
Occult Intra-articular Knee Injuries in Children With Hemarthrosis. ( 24753236 )
2014
33
Anticoagulant-induced hemarthrosis presenting as anterior shoulder dislocation. ( 25043625 )
2014
34
Spontaneous hemarthrosis following fibrinolytic therapy for acute myocardial infarction: a case report and literature review. ( 25417208 )
2014
35
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease. ( 24418945 )
2014
36
Selective arterial embolization with gelatin particles for refractory knee hemarthrosis. ( 23846552 )
2013
37
Recurrent hemarthrosis : an unusual cause. ( 23680622 )
2013
38
Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. ( 24283895 )
2013
39
Recurrent hemarthrosis after total knee arthroplasty caused by the impingement of a remnant lateral meniscus: A case report. ( 24231622 )
2013
40
Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization. ( 24252538 )
2013
41
A case of selective arterial embolization for recurrent hemarthrosis after total knee arthroplasty. ( 22237971 )
2013
42
Geniculate artery embolization in the management of spontaneous recurrent hemarthrosis of the knee: case series. ( 23433418 )
2013
43
A case of bilateral hemarthrosis due to pseudoaneurysms in a patient on anticoagulation therapy. ( 23669803 )
2013
44
Hemophilic chronic synovitis: therapy of hemarthrosis using endovascular embolization of knee and elbow arteries. ( 23150120 )
2013
45
MRI findings in adolescent patients with acute traumatic knee hemarthrosis. ( 23147616 )
2012
46
Transarterial embolization for the management of hemarthrosis of the knee. ( 22154590 )
2012
47
Intra-articular nodular fasciitis of the knee: a rare cause of recurrent hemarthrosis. ( 21431289 )
2012
48
Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin. ( 22764328 )
2012
49
Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)--a cross-sectional analysis. ( 22874525 )
2012
50
Knee hemarthrosis after arthroscopic surgery in an athlete with low factor XIII activity. ( 23031577 )
2012

Variations for Hemarthrosis

Expression for Hemarthrosis

Search GEO for disease gene expression data for Hemarthrosis.

Pathways for Hemarthrosis

Pathways related to Hemarthrosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 BGLAP F10 F7 F8 F9
2
Show member pathways
12.8 F10 F7 F8 F9 VWF
3
Show member pathways
12.39 F10 F7 F8 F9
4
Show member pathways
11.76 F10 F7 F8 F9 VWF
5
Show member pathways
11.59 BGLAP F10 F7 F9
6 11.5 F10 F7 F8 F9 VWF
7 11.13 BGLAP SPP1
8 11.09 BGLAP SPP1
9 11 BGLAP SPP1
10 10.1 BGLAP F10 F7 F9

GO Terms for Hemarthrosis

Cellular components related to Hemarthrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 BGLAP F10 F7 F8 F9 SPP1
2 extracellular region GO:0005576 9.7 BGLAP F10 F7 F8 F9 SPP1
3 vesicle GO:0031982 9.5 BGLAP F7 SPP1
4 platelet alpha granule lumen GO:0031093 9.37 F8 VWF
5 Golgi lumen GO:0005796 9.26 BGLAP F10 F7 F9
6 endoplasmic reticulum lumen GO:0005788 9.1 BGLAP F10 F7 F8 F9 SPP1

Biological processes related to Hemarthrosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ER to Golgi vesicle-mediated transport GO:0006888 9.55 BGLAP F10 F7 F8 F9
2 osteoblast differentiation GO:0001649 9.49 BGLAP SPP1
3 response to estrogen GO:0043627 9.48 BGLAP F7
4 response to nutrient levels GO:0031667 9.46 BGLAP F7
5 biomineral tissue development GO:0031214 9.43 BGLAP SPP1
6 blood coagulation, intrinsic pathway GO:0007597 9.43 F8 F9 VWF
7 response to vitamin D GO:0033280 9.4 BGLAP SPP1
8 blood coagulation, extrinsic pathway GO:0007598 9.37 F10 F7
9 blood coagulation GO:0007596 9.35 F10 F7 F8 F9 VWF
10 response to vitamin K GO:0032571 9.32 BGLAP F7
11 hemostasis GO:0007599 9.02 F10 F7 F8 F9 VWF

Molecular functions related to Hemarthrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.5 F10 F7 F9
2 serine-type endopeptidase activity GO:0004252 9.33 F10 F7 F9
3 endopeptidase activity GO:0004175 9.26 F7 F9
4 calcium ion binding GO:0005509 9.26 BGLAP F10 F7 F9
5 serine-type peptidase activity GO:0008236 8.8 F10 F7 F9

Sources for Hemarthrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....